12391100
story
John Bayko writes
"Mentioned on Slashdot a couple of years ago, the drug dichloroacetate (DCA) has finally finished its first clinical trial against brain tumors in humans. Drug companies weren't willing to test a drug they could not patent, so money was raised in the community through donations, auctions, and finally government support, but the study was still limited to five patients. It showed extremely positive results in four of them. This episode raises the question of what happens to all the money donated to Canadian and other cancer societies, and especially the billions spent buying merchandise with little pink ribbons on it, if not to actual cancer research like this."
11940424
story
reverseengineer writes
"The US Food and Drug Administration has given its first first approval for a therapeutic cancer vaccine. In a clinical trial 'involving 512 men, those who got Provenge (sipuleucel-T) had a median survival of 25.8 months after treatment, while those who got a placebo lived a median of 21.7 months. After three years, 32 percent of those who got Provenge were alive, compared with 23 percent of those who got the placebo. ... "The big story here is that this is the first proof of principle and proof that immunotherapy works in general in cancer, which I think is a huge observation," said Dr. Philip Kantoff, chief of solid tumor oncology at the Dana-Farber Cancer Institute in Boston and the lead investigator in Dendreon's largest clinical trial for the drug. "I think this is a very big thing and will lead to a lot more enthusiasm for the approach."'"
